Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
Erika Vacchelli
, Fernando Aranda
,
Alexander Eggermont
, Jérôme Galon
, Catherine Sautès-Fridman
, Laurence Zitvogel
, Guido Kroemer
, Lorenzo Galluzzi
Research output
:
Contribution to journal
›
Review article
›
peer-review
79
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
In Cancer
100%
Cancer Therapy
100%
Tumor Targeting
100%
Monoclonal Antibody
100%
Clinical Trials
66%
Antineoplastic Agents
66%
Hematological Malignancies
33%
Tumor-stroma Interaction
33%
U.S. Food
33%
Tumor Antigen
33%
Malignant Cells
33%
Cancer Patients
33%
Solid Malignancies
33%
Rituximab
33%
Immune System
33%
Armamentarium
33%
Stromal Component
33%
Immune Effectors
33%
Distinct Mechanism
33%
Immunomodulatory Effect
33%
Three-class
33%
Oncoimmunology
33%
International Regulatory Agencies
33%
Scientific Background
33%
Anti-CD20
33%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Malignant Neoplasm
100%
Monoclonal Antibody
100%
Clinical Trial
66%
Anticarcinogen
66%
Rituximab
33%
Tumor Antigen
33%
Immunology and Microbiology
Monoclonal Antibody
100%
Tumor Antigen
50%
Immune System
50%
Stroma
50%
CD20
50%
Immunity
50%
Antineoplastic Activity
50%
Rituximab
50%